Write a 100-350 word essay about the enzyme human SLC35C1. Provide information related to enzyme: i) function, ii) reaction pathways, ii) Location, and iv) diseases. In writing include these four subheadings

### Function
Human SLC35C1 is a nucleotide sugar transporter enzyme responsible for the transport of GDP-fucose into the Golgi apparatus. GDP-fucose is crucial for the fucosylation of glycoproteins and glycolipids, a process that involves adding fucose, a sugar molecule, to these macromolecules. Fucosylation plays an essential role in various biological processes, including cell adhesion, immune response, and blood group antigen expression.

### Reaction Pathways
SLC35C1 functions within the fucosylation pathway, where it transports GDP-fucose from the cytosol into the Golgi lumen. Inside the Golgi, GDP-fucose is used by fucosyltransferases to add fucose to glycoproteins and glycolipids, a modification that is vital for the proper function of these molecules. This process is critical for the synthesis of selectin ligands, which are important for leukocyte trafficking, as well as for the formation of blood group antigens and the stabilization of protein structures.

### Location
SLC35C1 is localized in the membrane of the Golgi apparatus, the site where glycosylation processes, including fucosylation, occur. The localization of SLC35C1 in the Golgi membrane allows it to efficiently transport GDP-fucose into the Golgi lumen, ensuring that fucosyltransferases have sufficient substrate to perform their function in modifying glycoproteins and glycolipids. This transport is essential for maintaining normal cellular functions that depend on proper glycosylation.

### Diseases
Mutations in the SLC35C1 gene cause a rare congenital disorder known as Leukocyte Adhesion Deficiency Type II (LAD II), also referred to as Congenital Disorder of Glycosylation Type IIc (CDG IIc). This disorder is characterized by severe immunodeficiency, recurrent infections, developmental delays, and distinctive facial features. The disease arises because defective GDP-fucose transport leads to impaired fucosylation, disrupting the function of glycoproteins and glycolipids involved in immune cell adhesion and other critical processes. Understanding SLC35C1â€™s role is vital for diagnosing LAD II and exploring potential therapeutic approaches to manage or treat the condition.